布地奈德和沙丁胺醇治疗儿童咳嗽变异性哮喘疗效和安全性研究

Efficacy and safety of budesonide combined with salbutamol in the treatment of children with cough variant asthma

目的探讨布地奈德和沙丁胺醇治疗儿童咳嗽变异性哮喘疗效和安全性。方法将2014年10月至2016年10月期间淮安市楚州中医院儿科诊治的70例咳嗽变异性哮喘患儿根据随机数表法分为观察组和对照组,每组35例。对照组采用布地奈德吸入治疗,观察组采用布地奈德联合沙丁胺醇治疗,治疗周期均为4周。比较两组患儿的治疗效果、肺功能指标改善情况、血清炎性介质水平变化及不良反应发生情况。结果观察组和对照组患儿的临床控制率(97.1%vs 80.0%)及治疗总有效率(62.9%vs 37.1%)比较,观察组均明显高于对照组,差异均有统计学意义(P<0.05);治疗后,两组患儿的第1秒用力呼气容积(FEV1)、呼气峰流速值(PEF)均明显升高,且观察组和对照组的FEV1[(2.27±0.30)L vs(1.93±0.30)L]及PEF[(4.57±0.99)L/s vs(3.88±0.79)L/s]比较,观察组改善程度明显优于对照组,差异均有统计学意义(P<0.05);治疗后,两组患儿的免疫球蛋白E(Ig E)、白介素-5(IL-5)均显著降低,白介素-10(IL-10)显著升高,且观察组和对照组的Ig E[(118.2±38.1)IU/m L vs(169.3±46.3)IU/m L]、IL-5[(22.5±5.2)pg/m L vs(29.5±6.3)pg/m L]及IL-10[(38.2±8.2)pg/m L vs(26.6±7.4)pg/m L]比较,观察组改善程度明显优于对照组,差异均有统计学意义(P<0.05);观察组不良反应发生率为14.3%,与对照组的8.6%比较,差异无统计学意义(P>0.05)。结论布地奈德联合沙丁胺醇治疗儿童咳嗽变异性哮喘具有良好的疗效,且安全性较好。

Objective To investigate the efficacy and safety of budesonide combined with salbutamol in treatment of children with cough variant asthma. Methods Seventy children with cough variant asthma in Department of Pediatrics, Huai＇an Chuzhou Hospital of Traditional Chinese Medicine from Oct. 2014 to Oct. 2016 were randomly divided into the observation group and the control group according to the random number table, with 35 cases in each group.The control group was treated with budesonide, and the observation group was treated with budesonide combined with salbutamol. The treatment cycle was 4 weeks. The therapeutic effect, the improvement of pulmonary function index, the level of serum inflammatory mediators and the incidence of adverse reactions were compared between the two groups.Results The clinical control rate and the total effective rate were 97.1%, 62.9% in the observation group versus 80.0%,37.1% in the control group（P〈0.05）. After treatment, forced expiratory volume in one second（FEV1） and peak expiratory flow（PEF） of the two groups were significantly increased, and the improvement in the observation group was significantly better than that in the control group（P〈0.05）, with（2.27±0.30） L in the observation group vs（1.93±0.30） L in the control group for FEV1 and（4.57±0.99） L/s vs（3.88±0.79） L/s for PEF. After treatment, immunoglobulin E（Ig E）, interleukin（IL-5） of the two groups were significantly reduced and IL-10 significantly increased, and the improvement in observation group was significantly better than that in the control group（P〈0.05）, with（118.2 ± 38.1） IU/m L vs（169.3 ±46.3） IU/m L for Ig E,（22.5±5.2） pg/m L vs（29.5±6.3） pg/m L for IL-5 and（38.2±8.2） pg/m L vs（26.6±7.4） pg/m L for IL-10. improved significantly better than the control group（P〈0.05）. The incidence of adverse reactions in the observation group was 14.3%, as compared with 8.6% in the control group（P〈0.05）. Conclusion In children with cough variant asthma, budesonide combined with salbutamol has significant curative effect and good safety.